Verified Nov 2026
Other
·
Bagsvaerd, Capital Region of Denmark
·
Since 1923
Novo Nordisk is a global healthcare company founded in 1923 and headquartered in Bagsværd, Denmark. It employs 50,000–100,000 people and generates over $10 billion in annual revenue. The company develops biological medicines for diabetes, obesity, hemophilia, and other chronic diseases across 170 countries. In 2026, Novo Nordisk Canada partnered with Rexall Pharmacy to provide home delivery services for obesity and diabetes medications.
Novo Nordisk Canada Inc. at a glance
Revenue
$10B+
Est. band
Employees
50,000-100,000
Founded
1923
Headquarters
Bagsvaerd, Capital Region of Denmark
Import activity
7389
Industries
Automotive
Electric Vehicles
Medical
Renewable Energy
Industrial Equipment
Sourcing and import activity
From US customs bill-of-lading records
US sea imports
7389
Named foreign suppliers
50
Top origins
Germany · Netherlands · China · Malaysia

Shared foreign counterparties do not establish that these companies buy from Novo Nordisk Canada Inc..
What this tells a buyer
The company received 7,389 recorded shipments, with primary inbound sourcing from Denmark, Germany, Netherlands, China, Malaysia, and Belgium, drawing on suppliers across 24 countries including Japan, Taiwan, and Brazil.
Novo Nordisk manufactures insulins, GLP-1 receptor agonists, oral anti-diabetics, obesity treatments, hemophilia therapies, and growth hormone products, supported by investments in next-generation biologics and digital health tools.
The company operates as a private entity with over 69,000 employees worldwide and maintains a dual-division structure focused on Diabetes and Obesity Care alongside Biopharmaceuticals.
Source: US customs bill-of-lading records and public filings · Last verified Nov 13, 2026
STABILITY SIGNALS
Established & active
103 years in operation (founded 1923).
7,389 US import shipments on record.
Overview
Novo Nordisk is a global healthcare company founded in 1923 and headquartered in Bagsværd, Denmark. It employs 50,000–100,000 people and generates over $10 billion in annual revenue. The company develops biological medicines for diabetes, obesity, hemophilia, and other chronic diseases across 170 countries. In 2026, Novo Nordisk Canada partnered with Rexall Pharmacy to provide home delivery services for obesity and diabetes medications.
At a glance
Attribute | Detail |
|---|---|
Founded | 1923 |
Headquarters | Bagsvaerd, Capital Region of Denmark |
Employees | 50,000-100,000 |
Revenue | $10B+ (estimated) |
What Novo Nordisk Canada Inc. makes
Novo Nordisk manufactures insulins, GLP-1 receptor agonists, oral anti-diabetics, obesity treatments, hemophilia therapies, and growth hormone products, supported by investments in next-generation biologics and digital health tools.
Trade and customs footprint
The company received 7,389 recorded shipments, with primary inbound sourcing from Denmark, Germany, Netherlands, China, Malaysia, and Belgium, drawing on suppliers across 24 countries including Japan, Taiwan, and Brazil. US customs bill-of-lading records list 7389 inbound shipments across 50 foreign suppliers, with top origins including Germany · Netherlands · China · Malaysia.
Latest developments
2026-09-18 — Novo Nordisk Canada Inc. Press Releases | Cision (newswire.ca)
2026-05-13 — Novo Nordisk Canada and Rexall Pharmacy partner to offer convenience, support, and home delivery for Canadians taking Ozempic® and Wegovy® (newswire.ca)
2026-04-09 — Novo-partner receives USD 57 million from the Canadian government (medwatch.com)
2026-01-20 — Aspect Biosystems and Novo Nordisk enter new phase of partnership to develop curative medicines for diabetes (aspectbiosystems.com)
2026-01-07 — Novo Nordisk Canada considers renamed lower-price Ozempic (ctvnews.ca)
2025-10-15 — Sogroya® (somapacitan injection) now available in Canada as the first and only once-weekly treatment for both children and adults living with growth hormone deficiency (newswire.ca)
Company details
The company operates as a private entity with over 69,000 employees worldwide and maintains a dual-division structure focused on Diabetes and Obesity Care alongside Biopharmaceuticals. Novo Nordisk Canada Inc. was founded in 1923, has an estimated 50,000-100,000 employees, and is headquartered in Bagsvaerd, Capital Region of Denmark. On the LightSource stability read it is rated "Established & active": 103 years in operation (founded 1923). 7,389 US import shipments on record.
Frequently asked questions
What does Novo Nordisk Canada Inc. do?
Novo Nordisk is a global healthcare company founded in 1923 and headquartered in Bagsværd, Denmark. It employs 50,000–100,000 people and generates over $10 billion in annual revenue. The company develops biological medicines for diabetes, obesity, hemophilia, and other chronic diseases across 170 countries. In 2026, Novo Nordisk Canada partnered with Rexall Pharmacy to provide home delivery services for obesity and diabetes medications.
Where is Novo Nordisk Canada Inc. headquartered?
Novo Nordisk Canada Inc. is headquartered in Bagsvaerd, Capital Region of Denmark.
When was Novo Nordisk Canada Inc. founded?
Novo Nordisk Canada Inc. was founded in 1923.
How big is Novo Nordisk Canada Inc.?
Novo Nordisk Canada Inc. has an estimated 50,000-100,000 employees, with revenue in the $10B+ range (estimated).
Does Novo Nordisk Canada Inc. import from overseas suppliers?
US customs bill-of-lading records show 7389 inbound shipments for Novo Nordisk Canada Inc., with top origins including Germany · Netherlands · China · Malaysia.
Related suppliers
Explore other suppliers in the LightSource directory:
Last verified Nov 2026. Is this your company? Request a correction.
Location & contact
Evaluating suppliers like these?
This profile is part of a public-data sample of the full LightSource directory. Book a demo to see the full LightSource marketplace and supplier discovery platform — 1M+ credible suppliers, with AI-run sourcing events.
